UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

June 30, 2026

Date of Report (Date of earliest event reported)

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan

(Address of principal executive offices)

886-6-3121716

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 30, 2026, at 10:00 a.m. Eastern Time, Advanced Biomed Inc. (the “Company”) held its annual meeting of stockholders (the “Meeting”) at No. 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan. Holders of 1,422,573.80 shares of the Company’s common stock were present in person or by proxy at the Meeting, representing approximately 86.105% of the 1,652,133 shares of common stock issued and outstanding and entitled to vote at the Meeting as of the close of business on May 29, 2026, the record date for the Meeting, and therefore constituting a quorum. Five proposals were submitted to the stockholders for consideration at the Meeting. Based on the final tabulation of votes, each director nominee was elected and each of the proposals was approved. The final voting results for each matter submitted to a vote at the Meeting are as follows:

Proposal 1: To elect the five (5) director nominees named below to serve on the Board of Directors until the next annual meeting of stockholders and until their respective successors are duly elected and qualified.

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement (“Say-on-Pay”).

Proposal 3: To recommend, on a non-binding, advisory basis, the frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. Frequency results:

Proposal 4: To ratify the appointment of WWC, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026.

Proposal 5: To approve the adjournment of the Meeting, if necessary or appropriate, to solicit additional proxies in favor of any of the foregoing proposals.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.